May 26, 2026 | Press Releases
Live Presentation and Q&A: Thursday, May 28, 2026 12 PM EDTKing of Prussia, Pennsylvania–(Newsfile Corp. – May 26, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using...
May 12, 2026 | Press Releases
Live virtual fireside chat — investors, advisors, and life sciences analysts invited to attendFeaturing Dermatologist Mary Spellman, M.D., with Phio CEO Robert Bitterman and Force Family Office CEO Steven SaltzsteinKing of Prussia, Pennsylvania–(Newsfile...
May 7, 2026 | Press Releases
Completion of Lead Clinical Candidate PH-762 Dose Escalation Trial for Treatment of Skin Cancer with Favorable Safety and Pathology DataKey Development Agreements Secured for Nonclinical Toxicology and U.S. cGMP Clinical Supply ManufacturingKing of Prussia,...
Apr 23, 2026 | Press Releases
Live Presentation and Q&A: Wednesday, April 29, 2026 12 PM EDTKing of Prussia, Pennsylvania–(Newsfile Corp. – April 23, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics...
Apr 13, 2026 | Press Releases
Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend this virtual eventR. Todd Plott, M.D., Chief Medical Officer, Epiphany Dermatology will join Robert Bitterman, Phio Pharmaceuticals and Steven Saltzstein, Force Family...
Apr 9, 2026 | Press Releases
Investors and Advisors, and Life Sciences Analysts are Invited to Attend the New York City Event; Virtual Webcast Link Available BelowKing of Prussia, Pennsylvania–(Newsfile Corp. – April 9, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a...
